Square Pharmaceuticals (DHA:SQURPHARMA) Total Liabilities : BDT18,860 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Square Pharmaceuticals Total Liabilities?

Square Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 was BDT18,860 Mil.

Square Pharmaceuticals's quarterly Total Liabilities increased from Jun. 2023 (BDT6,619.66 Mil) to Sep. 2023 (BDT6,909.28 Mil) and increased from Sep. 2023 (BDT6,909.28 Mil) to Dec. 2023 (BDT18,860.18 Mil).

Square Pharmaceuticals's annual Total Liabilities increased from Jun. 2021 (BDT4,557.12 Mil) to Jun. 2022 (BDT6,554.84 Mil) and increased from Jun. 2022 (BDT6,554.84 Mil) to Jun. 2023 (BDT6,619.66 Mil).

Square Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Square Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Square Pharmaceuticals Total Liabilities Chart

Square Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Liabilities

Get a 7-Day Free Trial

4,265.44

4,514.30

4,557.12

6,554.84

6,619.66

Square Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															17,263.68	8,051.07	6,619.66	6,909.28	18,860.18

Square Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Square Pharmaceuticals's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	4229.146	+	(1368.357	+	1022.153
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	6,620

Total Liabilities	=	Total Assets (A: Jun. 2023 )	-	Total Equity (A: Jun. 2023 )
	=	121816.305	-	115196.649
	=	6,620

Square Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	16706.414	+	(1049.336	+	1104.425
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	18,860

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	135934.014	-	117073.839
	=	18,860

Square Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Square Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Square Pharmaceuticals (DHA:SQURPHARMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Square Pharmaceuticals PLC (DHA:SQURPHARMA) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

Square Centre, 48, Mohakhali Commercial Area, Dhaka, BGD, 1212

Website

http://www.squarepharma.com.bd

Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceuticals products, Basic chemical products, and animal health products. It manufactures drugs like paracetamol, clotrimazole, antiallergic, Nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs. The company operates in Bangladesh and sells its products locally and internationally. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs.

Square Pharmaceuticals (DHA:SQURPHARMA) Headlines

No Headlines